TG Therapeutics Inc (TGTX)
followers
·
Follow
Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Michael S. Weiss
Employees:
290
2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK, NY, 10014
(212) 554-4484
-
Formally known as:
- MANHATTAN PHARMACEUTICALS, INC.
- MANHATTAN PHARMACEUTICALS, INC.
- TG THERAPEUTICS, INC. NEW COMMON
Date | Ratio |
---|---|
2011-07-14 | 1:50 |
2012-04-30 | 100:5625 |
TG Therapeutics, Inc. focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors. TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor.
All 13F Filers | Prior | Change | Hedge Funds 1 | Prior | Change |
---|